Eliza PS Tsou, PhD
Frederick G L Huetwell Research Professor of Rheumatology II
Assistant Professor of Internal Medicine
Assistant Professor of Pharmacology
Medical School
Michigan Medicine
Internal Medicine/Rheumatology
2800 Plymouth Road, Building 20, Room 1822
Ann Arbor, Michigan 48109
[email protected]
Internal Medicine/Rheumatology
2800 Plymouth Road, Building 20, Room 1822
Ann Arbor, Michigan 48109
Available to mentor
Eliza PS Tsou, PhD
Assistant Professor
Manage Your Profile
Qualifications
-
PhD, Department of Pharmaceutical Sciences. School of PharmacyUniversity at Buffalo, State University of New York, Buffalo, NY, United States
2002 - 2008
-
BSc, Department of PharmacyNational Taiwan University, Taipei, Taiwan
1997 - 2001
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberGlobal REACH
Recent Publications
-
Ma F, Tsou PS, Gharaee-Kermani M, Plazyo O, Xing X, Kirma J, Wasikowski R, Hile GA, Harms PW, Jiang Y, Xing E, Nakamura M, Ochocki D, Brodie WD, Pillai S, Maverakis E, Pellegrini M, Modlin RL, Varga J, Tsoi LC, Lafyatis R, Kahlenberg JM, Billi AC, Khanna D, Gudjonsson JE. Nature Communications, 2024 Dec 1; 15 (1):Journal ArticleSystems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis
DOI:10.1038/s41467-023-44645-6 PMID: 38172207 -
van Straalen KR, Ma F, Tsou PS, Plazyo O, Gharaee-Kermani M, Calbet M, Xing X, Sarkar MK, Uppala R, Harms PW, Wasikowski R, Nahlawi L, Nakamura M, Eshaq M, Wang C, Dobry C, Kozlow JH, Cherry-Bukowiec J, Brodie WD, Wolk K, Uluçkan Ö, Mattichak MN, Pellegrini M, Modlin RL, Maverakis E, Sabat R, Kahlenberg JM, Billi AC, Tsoi LC, Gudjonsson JE. Journal of Clinical Investigation, 2024 Feb 10; 134 (3):Journal ArticleSingle-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa
DOI:10.1172/JCI169225 PMID: 38051587 -
Shi B, Tsou PS, Ma F, Mariani MP, Mattichak MN, LeBrasseur NK, Chini EN, Lafyatis R, Khanna D, Whitfield ML, Gudjonsson JE, Varga J. Journal of Investigative Dermatology, 2023 Apr 1; 143 (4): 661 - 664.e5.Journal ArticleSenescent Cells Accumulate in Systemic Sclerosis Skin
DOI:10.1016/j.jid.2022.09.652 PMID: 36191640 -
Gan Y, Liang W, Liu C, Yalavarthi S, Warnock M, Sabb K, Sarosh C, Schaefer JK, Tambralli A, Madison JA, Emal CD, Tsou P-S, Shi H, Zuo Y, Lawrence DA, Knight JS. J Autoimmun, 2026 Apr 27; 161: 103563Journal ArticleEndothelial cell-derived plasminogen activator inhibitor-1 potentiates thrombosis in antiphospholipid syndrome.
DOI:10.1016/j.jaut.2026.103563 PMID: 42048835 -
Nunez D, Volkov JR, Little C, Ghosh M, Tsou P-S, Furmanak T, Dey P, Tsoi LC, Zahn C, Bogle R, Cai Y, Fox J, Stadanlick J, Werner M, Vorndran Z, Ishikawa L, Ellis A, Williams J, Cicarelli J, Flannagan S, Kobulsky D, Lam Q, Schmitt C, Nezhad F, Thompson D, Braccia D, Rivera TG, Tummala R, Gudjonsson JE, Ross C, Binder G, Chang D, Basu S, Khanna D. Mol Ther Adv, 2026 Mar 12; 34 (1): 201663Journal ArticleCase study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.
DOI:10.1016/j.omta.2025.201663 PMID: PMC13182784 -
Shah K, Verma P, Hamil T, Dey P, Bale S, Yalavarthi B, Tsou P-S, Gudjonsson JE, Khanna D, Varga J, Bhattacharyya S. J Invest Dermatol, 2026 Mar 6;Journal ArticleNintedanib Attenuates Profibrotic Gene Expression in a 3D Organotypic Culture Model of Systemic Sclerosis Skin Fibrosis.
DOI:10.1016/j.jid.2026.01.046 PMID: 41796853 -
Grant K, Matossian S, Rosek A, Sturza J, Chen L, Madubata C, Barnett D, Neely J, Torok K, Kahlenberg JM, Tsou E, Turnier J. 2026 Mar 24;Proceeding / Abstract / PosterEndothelial cell mediators reflecting angiopoietin and interferon pathway activation characterize juvenile dermatomyositis disease activity and autoantibody subgroups
-
Kaundal U, Tsou P-S, Sahu M, Huang M, Boyden SE, Woodford CM, Shriner D, Stenson E, Safran SA, Zhou Y, Talley TA, Gudapati K, Zhang X, Kunishita Y, Wang J, Shah AA, Mayes MD, Doumatey AP, Bentley AR, Domsic R, Medsger TA, Ramos PS, Silver RM, Steen V, Varga J, Hsu V, Saketkoo LA, Schiopu E, Gordon JK, Criswell LA, Gladue H, Derk C, Bernstein EJ, Bridges SL, Shanmugam V, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Mullikin J, Thomas JW, Dell'Orso S, Randazzo D, Adeyemo A, Remmers EF, Schwartzberg PL, Aksentijevich I, Rotimi C, Wigley FM, Wang RA, Boin F, Khanna D, Lafyatis R, Kastner DL, Gourh P. Ann Rheum Dis, 2026 Feb 4;Journal ArticleGain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
DOI:10.1016/j.ard.2025.12.015 PMID: 41644364
Featured News & Stories
Health Lab
Protein found in rheumatic diseases causes inflammation in COVID-19 patients
Research on the inflammatory mediator called sCD13 has identified this molecule and its receptors as new targets for treatment of autoimmune rheumatic diseases. The data suggests that sCD13 may also be of great importance in severe complications of COVID-19.
Health Lab
Targeting and blocking sCD13 protein could lead to systemic sclerosis treatment
Targeting and blocking the sCD13 protein from interacting with the B1R protein can pave the way for new fibrosis and systemic sclerosis treatments.